Answers are grounded in this paper and cite their sources.
Background Osteoporosis (OP) is marked by lower bone mineral density (BMD) and progressive deterioration of bone microarchitecture, which mainly affects postmenopausal women and exposes individuals at risk for severe fragility fractures. Sjögren’s disease (SjD) is a chronic autoimmune disorder that is now recognized as an independent risk factor for OP and characterized by lymphocytic infiltration of exocrine glands, leading to xerostomia and xerophthalmia. Chronic inflammatory pathways, metabolic disorders such as distal renal tubular acidosis (dRTA), vitamin D deficiency, and the osteotoxic effects of long-term glucocorticoid therapy are mechanistically linked to the two pathological conditions, which exhibit a strong demographic predisposition. Standard diagnostic methods often underestimate the actual fracture risk in this population. Aim of the work To describe the metabolic and immunopathological processes that explain osteoporosis in Sjögren’s disease and to assess the advancements in diagnosis and treatment approaches essential to sustain bone health in this population. Main body of the abstract In Sjögren’s disease, skeletal fragility is caused by deregulation of the RANKL/RANK/OPG axis and Wnt signalling, which gets exacerbated by pro-inflammatory cytokines such as TNF-α, IL-1, IL-6, and IL-17. Bone loss is triggered by renal involvement, specifically distal renal tubular acidosis (dRTA), resulting in hypophosphatemia, hypercalciuria, and chronic metabolic acidosis. Osteoblast function and immunological modulation are further restricted by vitamin D insufficiency, which is caused by inadequate direct sunlight exposure and impaired renal hydroxylation, further increasing the rate of bone loss and is independently related to elevated disease activity, an increased risk of lymphoma, and poor cardiorenal outcomes. The Trabecular Bone Score (TBS) enables significant microarchitectural risk stratification beyond BMD alone, capturing skeletal fragility undetected by DXA-based T-scoring, and FRAX consistently underestimates fracture probability in SjD. Short conclusion Managing osteoporosis in Sjögren’s disease requires a multidisciplinary approach. This includes bone-specific medication, targeted calcium and vitamin D supplements, and individualised dietary and physical activity plans adapted to address xerostomia and chronic fatigue.
No takes yet. Share an insight, caveat, or question.
M. et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: